\uff5e Axsome Therapeutics\u793e\u3068Veeva Systems\u793e\u306e\u6226\u7565\u7684\u30d1\u30fc\u30c8\u30ca\u30b7\u30c3\u30d7\u306b\u3088\u308a\u3001<\/p>\n
Axsome\u793e\u306bVeeva\u304c\u958b\u767a\u3057\u305f\u6700\u65b0\u30c7\u30b8\u30bf\u30eb\u6280\u8853\u3078\u306e\u30a2\u30af\u30bb\u30b9\u3092\u63d0\u4f9b \uff5e<\/p>\n
<\/p>\n
2020\u5e7411\u670825\u65e5<\/p>\n
Veeva Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n
\u4e2d\u67a2\u795e\u7d4c\u7cfb (CNS) \u75be\u60a3\u3092\u6291\u5236\u3059\u308b\u65b0\u898f\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3092\u5c02\u9580\u3068\u3059\u308b\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696dAxsome Therapeutics\u793e\u3010NASDAQ:AXSM\u3011(\u4ee5\u4e0bAxsome\u793e) \u3068\u3001Veeva Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b Veeva)\u306f\u3001Axsome\u793e\u306e\u3088\u308a\u5148\u9032\u7684\u306aDigital-Centric Commercialization (DCC™) \u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u69cb\u7bc9\u5f37\u5316\u3092\u76ee\u7684\u3068\u3057\u305f\u3001\u6226\u7565\u7684\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Veeva\u306f\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u696d\u754c\u5411\u3051\u30af\u30e9\u30a6\u30c9\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002(\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001Veeva\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n <\/p>\n \u4eca\u56de\u306eVeeva\u3068\u306e\u63d0\u643a\u306f\u3001\u6765\u5e74\u3092\u76ee\u9014\u306b2\u7a2e\u985e\u306eCNS\u6cbb\u9a13\u85ac (\u3046\u3064\u75c5\u85acAXS-05\u3068\u7247\u982d\u75db\u85acAXS-07) \u306e\u4e0a\u5e02\u306b\u5099\u3048\u3001Axsome\u793e\u306eDCC\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u69cb\u7bc9\u3092\u9032\u3081\u308b\u4e00\u74b0\u3068\u3057\u3066\u7d50\u3070\u308c\u305f\u3082\u306e\u3067\u3059\u3002Axsome\u793e\u306eDCC\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u5c02\u9580\u306e\u30c7\u30b8\u30bf\u30eb\u30c4\u30fc\u30eb\u3001\u5c02\u6709\u30c7\u30fc\u30bf\u3068\u30a2\u30ca\u30ea\u30c6\u30a3\u30af\u30b9\u3001\u7d71\u5408\u3055\u308c\u305f\u5404\u7a2e\u30b7\u30b9\u30c6\u30e0\u3001\u304a\u3088\u3073\u30a4\u30f3\u30c6\u30ea\u30b8\u30a7\u30f3\u30c8\u306a\u30aa\u30da\u30ec\u30fc\u30c6\u30a3\u30f3\u30b0\u30e2\u30c7\u30eb\u304c\u7d44\u307f\u8fbc\u307e\u308c\u305f\u3001\u30b3\u30de\u30fc\u30b7\u30e3\u30ea\u30bc\u30fc\u30b7\u30e7\u30f3\u3092\u5b9f\u73fe\u3059\u308b\u72ec\u81ea\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\u3067\u3059\u3002\u3053\u306e\u30c7\u30b8\u30bf\u30eb\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u3088\u308a\u3001Axsome\u793e\u306f\u533b\u5e2b\u3068\u60a3\u8005\u306e\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u3092\u6700\u9069\u5316\u3057\u3001\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u306e\u8cea\u3092\u9ad8\u3081\u3001\u5f93\u6765\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\u3068\u6bd4\u8f03\u3057\u3066\u8ca9\u4fc3\u6d3b\u52d5\u306e\u52b9\u679c\u3092\u5411\u4e0a\u3059\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n Axsome\u793e\u306eDCC\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u306f\u3001Veeva Commercial Cloud<\/a><\/strong>\u306e\u88fd\u54c1\u3068\u30b5\u30fc\u30d3\u30b9\u304c\u3059\u3079\u3066\u5229\u7528\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002\u4f8b\u3048\u3070\u3001\u30de\u30eb\u30c1\u30c1\u30e3\u30cd\u30ebVeeva CRM<\/a><\/strong>\u306f\u3001\u597d\u307f\u306e\u30c7\u30b8\u30bf\u30eb\u30c1\u30e3\u30cd\u30eb\u3084\u500b\u5225\u30c1\u30e3\u30cd\u30eb\u306b\u3088\u308b\u9867\u5ba2\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u306e\u6280\u8853\u57fa\u76e4\u3068\u3057\u3066\u5229\u7528\u3055\u308c\u3001\u533b\u7642\u5f93\u4e8b\u8005\u5411\u3051\u30e2\u30d0\u30a4\u30eb\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3MyVeeva for Doctors<\/a><\/strong>\u306f\u3001\u533b\u7642\u5f93\u4e8b\u8005\u3068Axsome\u793e\u306e\u9593\u3067\u52b9\u7387\u7684\u304b\u3064\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u306b\u5bfe\u5fdc\u3057\u305f\u30ea\u30a2\u30eb\u30bf\u30a4\u30e0\u30e1\u30c3\u30bb\u30fc\u30b8\u30f3\u30b0\u3092\u5b9f\u73fe\u3059\u308b\u624b\u6bb5\u3068\u3057\u3066\u3001Veeva Data Cloud<\/a><\/strong>\u306f\u3001\u52b9\u7387\u7684\u304b\u3064\u30bf\u30fc\u30b2\u30c3\u30c8\u3092\u7d5e\u3063\u305f\u4e0a\u5e02\u3092\u53ef\u80fd\u306b\u3059\u308b\u7e26\u65ad\u7684\u30c7\u30fc\u30bf\u3092\u53d6\u5f97\u3059\u308b\u624b\u6bb5\u3068\u3057\u3066\u5229\u7528\u3055\u308c\u307e\u3059\u3002<\/p>\n \u307e\u305f\u4eca\u56de\u306e\u6226\u7565\u7684\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u306b\u3088\u308a\u3001Axsome\u793e\u306fVeeva\u304c\u958b\u767a\u3057\u305f\u6700\u65b0\u30c7\u30b8\u30bf\u30eb\u6280\u8853\u306b\u3044\u3061\u65e9\u304f\u30a2\u30af\u30bb\u30b9\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u3001\u307e\u305fVeeva\u88fd\u54c1\u306e\u65b9\u5411\u3065\u3051\u3092\u652f\u63f4\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002\u3053\u306e\u65e9\u671f\u30a2\u30af\u30bb\u30b9\u306b\u3088\u308a\u3001Axsome\u793e\u304c\u5229\u7528\u3067\u304d\u308b\u30c7\u30b8\u30bf\u30eb\u30c4\u30fc\u30eb\u306e\u7bc4\u56f2\u304c\u5e83\u304c\u308a\u307e\u3059\u3002\u3055\u3089\u306bVeeva\u306e\u30d3\u30b8\u30cd\u30b9\u30b3\u30f3\u30b5\u30eb\u30c6\u30a3\u30f3\u30b0\u30c1\u30fc\u30e0\u304c\u3001\u8c4a\u304b\u306a\u5c02\u9580\u77e5\u8b58\u3068\u696d\u754c\u5168\u4f53\u306b\u308f\u305f\u308b\u6975\u3081\u3066\u5305\u62ec\u7684\u306a\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u30c7\u30fc\u30bf\u3084\u77e5\u898b\u3092\u63d0\u4f9b\u3057\u3066\u3001Axsome\u793e\u306e\u4e0a\u5e02\u6226\u7565\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u307e\u3059\u3002<\/p>\n Axsome\u793e\u306e\u6700\u9ad8\u7d4c\u55b6\u8cac\u4efb\u8005\u3067\u3042\u308bHerriot Tabuteau\u6c0f\uff08\u533b\u5b66\u58eb\uff09\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cVeeva\u306f\u3001\u60a3\u8005\u30b1\u30a2\u306e\u5411\u4e0a\u306b\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3068\u60c5\u71b1\u3092\u50be\u3051\u308b\u5f53\u793e\u306e\u30b3\u30df\u30c3\u30c8\u30e1\u30f3\u30c8\u3092\u7406\u89e3\u3057\u3066\u3044\u305f\u3060\u3051\u308b\u7406\u60f3\u7684\u306a\u30d1\u30fc\u30c8\u30ca\u30fc\u3067\u3059\u3002\u4eca\u56de\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u306b\u3088\u308a\u3001\u3055\u3089\u306b\u52b9\u679c\u7684\u3067\u8cc7\u672c\u52b9\u7387\u306e\u9ad8\u3044\u30b3\u30de\u30fc\u30b7\u30e3\u30eb\u6d3b\u52d5\u306e\u5b9f\u65bd\u306b\u5411\u3051\u305f\u3001\u5f53\u793e\u306eDigital-Centric Commercialization\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u5f37\u5316\u3059\u308b\u305f\u3081\u306e\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3001\u30c7\u30fc\u30bf\u3001\u30d3\u30b8\u30cd\u30b9\u30b3\u30f3\u30b5\u30eb\u30c6\u30a3\u30f3\u30b0\u304b\u3089\u6210\u308b\u5c02\u7528\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3092\u5b9f\u73fe\u3067\u304d\u307e\u3059\u3002\u300d<\/p>\n Veeva\u306e\u5275\u696d\u8005\u517cCEO\u3067\u3042\u308bPeter Gassner\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cAxsome\u793e\u306eDigital-Centric Commercialization\u6226\u7565\u306f\u3001\u88fd\u85ac\u696d\u754c\u306b\u5927\u304d\u306a\u8ee2\u63db\u3092\u3082\u305f\u3089\u3059\u3067\u3057\u3087\u3046\u3002\u5f53\u793e\u306fAxsome\u793e\u3068\u7dca\u5bc6\u306b\u9023\u643a\u3057\u3066\u3001\u9769\u65b0\u7684\u306a\u4e0a\u5e02\u8a08\u753b\u306e\u7b56\u5b9a\u3068\u5b9f\u65bd\u3092\u652f\u63f4\u3067\u304d\u308b\u3053\u3068\u3092\u5b09\u3057\u304f\u601d\u3063\u3066\u304a\u308a\u307e\u3059\u3002\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3001\u30c7\u30fc\u30bf\u3001\u30d3\u30b8\u30cd\u30b9\u30b3\u30f3\u30b5\u30eb\u30c6\u30a3\u30f3\u30b0\u306e\u7c8b\u3092\u7d50\u96c6\u3057\u3066\u3001\u696d\u754c\u306e\u767a\u5c55\u306b\u5c3d\u529b\u3057\u3066\u307e\u3044\u308a\u307e\u3059\u3002\u300d<\/p>\n <\/p>\n \u3010<\/strong>Axsome Therapeutics<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010<\/strong>Veeva Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010Forward Looking Statements Regarding Axsome\u3011 Therapeutics, Inc. \u3010Forward-looking Statements\u3011 Axsome\u793e\u306bVeeva\u304c\u958b\u767a\u3057\u305f\u6700\u65b0\u30c7\u30b8\u30bf\u30eb\u6280\u8853\u3078\u306e\u30a2\u30af\u30bb\u30b9\u3092\u63d0\u4f9b\u3002Axsome\u793e\u306f\u533b\u5e2b\u3068\u60a3\u8005\u306e\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u3092\u6700\u9069\u5316\u3057\u3001\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u306e\u8cea\u3092\u9ad8\u3081\u3066\u8ca9\u4fc3\u6d3b\u52d5\u306e\u52b9\u679c\u5411\u4e0a\u3092\u76ee\u6307\u3059\u3002<\/p>\n","protected":false},"author":131,"featured_media":44271,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-44270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/44270"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=44270"}],"version-history":[{"count":3,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/44270\/revisions"}],"predecessor-version":[{"id":44275,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/44270\/revisions\/44275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media\/44271"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=44270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=44270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=44270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nAxsome Therapeutics\u793e\u306f\u3001\u6cbb\u7642\u6cd5\u306e\u9078\u629e\u80a2\u304c\u9650\u3089\u308c\u305f\u4e2d\u67a2\u795e\u7d4c\u7cfb (CNS) \u75be\u60a3\u3092\u6291\u5236\u3059\u308b\u65b0\u898f\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3092\u5c02\u9580\u3068\u3059\u308b\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u3067\u3059\u3002CNS\u75be\u60a3\u306e\u6cbb\u7642\u6cd5\u306b\u6e80\u8db3\u3067\u304d\u306a\u3044\u591a\u304f\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001Axsome\u793e\u3067\u306f\u4eba\u751f\u3092\u5909\u3048\u308b\u6cbb\u7642\u85ac\u306e\u3088\u308a\u8fc5\u901f\u306a\u958b\u767a\u3068\u666e\u53ca\u306b\u52aa\u3081\u3066\u3044\u307e\u3059\u3002Axsome\u793e\u306eCNS\u5411\u3051\u4e3b\u529b\u88fd\u54c1\u7fa4\u306b\u306f\u3001AXS-05\u3001AXS-07\u3001AXS-09\u3001AXS-12\u3001AXS-14\u306e5\u3064\u306e\u81e8\u5e8a\u30b9\u30c6\u30fc\u30b8\u5019\u88dc\u304c\u542b\u307e\u308c\u307e\u3059\u3002AXS-05\u306f\u5927\u3046\u3064\u75c5\u6027\u969c\u5bb3 (MDD)\u3001\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7 (AD) \u306e\u8208\u596e\u75c7\u72b6\u3001\u304a\u3088\u3073\u7981\u7159\u306e\u6cbb\u7642\u3001AXS-07\u306f\u7247\u982d\u75db\u6025\u6027\u671f\u6cbb\u7642\u3001AXS-12\u306f\u30ca\u30eb\u30b3\u30ec\u30d7\u30b7\u30fc (\u7761\u7720\u767a\u4f5c) \u306e\u6cbb\u7642\u3001AXS-14\u306f\u7dda\u7dad\u7b4b\u75db\u75c7\u306e\u6cbb\u7642\u306e\u305f\u3081\u306b\u958b\u767a\u304c\u9032\u3081\u3089\u308c\u3066\u3044\u307e\u3059\u3002AXS-05\u3001AXS-07\u3001AXS-09\u3001AXS-12\u3001AXS-14\u306f\u3001\u3044\u305a\u308c\u3082FDA\u672a\u627f\u8a8d\u306e\u6cbb\u9a13\u85ac\u88fd\u54c1\u3067\u3059\u3002\u8a73\u7d30\u306f\u3001Axsome\u793e\u306eWeb\u30b5\u30a4\u30c8 (https:\/\/axsome.com\/) \u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002Axsome\u793e\u306f\u91cd\u8981\u306a\u975e\u516c\u958b\u60c5\u5831\u3092\u81ea\u793e\u306eWeb\u30b5\u30a4\u30c8\u3067\u516c\u8868\u3059\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n
\nVeeva Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067\u3001900\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002Veeva\u306f\u3001\u30b5\u30f3\u30d5\u30e9\u30f3\u30b7\u30b9\u30b3\u306e\u30d9\u30a4\u30a8\u30ea\u30a2\u306b\u672c\u793e\u3092\u7f6e\u304d\u3001\u30e8\u30fc\u30ed\u30c3\u30d1\u3001\u30a2\u30b8\u30a2\u3001\u30e9\u30c6\u30f3\u30a2\u30e1\u30ea\u30ab\u306b\u62e0\u70b9\u3092\u5c55\u958b\u3057\u3066\u3044\u307e\u3059\u3002
\n\u8a73\u3057\u304f\u306f\u3001https:\/\/veeva.com\/jp\/<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nCertain matters discussed in this press release are \u201cforward-looking statements\u201d. Axsome may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Axsome\u2019s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of Axsome\u2019s ongoing clinical trials and anticipated clinical trials for Axsome\u2019s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including Axsome\u2019s ability to fully fund our disclosed clinical trials, which assumes no material changes to Axsome\u2019s currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of Axsome\u2019s ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (\u201cNDA\u201d) for any of Axsome\u2019s current product candidates; Axsome\u2019s ability to fund additional clinical trials to continue the advancement of Axsome\u2019s product candidates; the timing of and Axsome\u2019s ability to obtain and maintain U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory authority approval of, or other action with respect to, Axsome\u2019s product candidates (including, but not limited to, with or without a special protocol assessment); the potential for Axsome\u2019s clinical trials to provide a basis for accelerated approval of Axsome\u2019s product candidates for the treatment of several indications and accelerate their development timelines and commercial paths to patients (including, but not limited to, with or without a breakthrough therapy designation); Axsome\u2019s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to Axsome, if at all; the successful implementation of Axsome\u2019s research and development programs and collaborations; the success of Axsome\u2019s license agreements; the acceptance by the market of Axsome\u2019s product candidates, if approved; Axsome\u2019s anticipated capital requirements, including Axsome\u2019s anticipated cash runway and Axsome\u2019s ability to fund Axsome\u2019s commercial launch, which assumes product approval; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within Axsome\u2019s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and Axsome undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company\u2019s website at veeva.com under the Investors section and on the SEC\u2019s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"